Log In
Print
BCIQ
Print
Print this Print this
 

labetuzumab-SN-38 (IMMU-130)

  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionAntibody against carcinoembryonic antigen (CEA)-related cell adhesion molecule 5 (CEACAM5; CD66e) conjugated with SN-38, the active metabolite of irinotecan
Molecular Target Carcinoembryonic antigen (CEA)-related cell adhesion molecule 5 (CEACAM5) (CD66e)
Mechanism of ActionBinds CEA; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationColorectal cancer
Indication DetailsTreat metastatic colorectal cancer in patients who have been previously treated with >=1 prior irinotecan-containing regimen; Treat relapsed or refractory colorectal cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today